Angiogenesis inhibitors increase tumor stem cells

Cindy H. Chau, William D. Figg*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

11 Scopus citations


The clinical efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway has recently been met with numerous phase III failures that showed modest survival benefits. Understanding the resistance mechanisms of antiangiogenic therapy is essential to overcoming the limited effectiveness of VEGF-pathway inhibitors. A recent study published in the Proceedings of the National Academy Sciences provides a novel explanation the treatment limitations of angiogenesis inhibitors and suggests a potential strategy to improve the clinical utility these agents.

Original languageEnglish
Pages (from-to)586-587
Number of pages2
JournalCancer Biology and Therapy
Issue number8
StatePublished - Jun 2012
Externally publishedYes


  • Angiogenesis
  • Cancer stem cells
  • Tumor hypoxia


Dive into the research topics of 'Angiogenesis inhibitors increase tumor stem cells'. Together they form a unique fingerprint.

Cite this